ArticleScientific reports2026
SHP2 promotes osteosarcoma via regulating STAT3/TET3/HOXB2 signaling.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative Molecular Insights and Computational Modeling of Multiple Myeloma and Osteosarcoma.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
To investigate the effect of SHP2 on the STAT3/TET3/HOXB2 signaling pathway in osteosarcoma, and its role in the proliferation, migration and invasion of osteosarcoma cells. First, bioinformatics analysis was used to identify relevant expressed genes. In vitro experiments, the expression levels of SHP2, p-STAT3, TET3, HOXB2, c-Myc, NANOG, NUSAP1 proteins in 143B cells and MG63 cells were detected by Western blot assay. The levels of TET3 and HOXB2 were detected by immunofluorescence double staining. Cell proliferation was detected by plate clone formation and CCK-8 assay. Cell migration was detected by scratch assay, and cell migration and invasion were detected by Transwell assay. Overexpression of SHP2 promotes osteosarcoma proliferation by upregulating STAT3, TET3 and HOXB2 proteins. VEGF activates RTK receptors and induces SHP2 autophosphorylation, which in turn activates STAT3 and enhances TET3 synthesis. TET3 then promotes HOXB2 transcription through demethylation. HOXB2 further upregulate the expression of c-Myc, NANOG and NUSAP1, ultimately driving the proliferation, migration and invasion of osteosarcoma and promoting tumor progression. This study confirmed that SHP2 promotes the proliferation, invasion and invasive ability of osteosarcoma cells by activating the STAT3/TET3/HOXB2 pathway, providing a new strategy for targeted treatment of osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.